Comanche Biopharma is a biopharmaceutical company that develops siRNA therapy for the treatment of preeclampsia.
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation. Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.
FYTO provides innovative solutions which improve the economic and environmental sustainability of agriculture for farmers around the world. FYTO is developing:
NOVEL NUTRIENT-DENSE CROPS that have ultra-high yields and ultra-low resource requirements, STATE-OF-THE ART CULTIVATION AND HARVESTING SYSTEMS for exceptional quality and consistency, CLIMATE-FRIENDLY METHODOLOGIES for resiliency and long-term sustainability, and a range of GROUNDBREAKING AGRICULTURAL PRODUCTS such as animal feed and biofertilizer.
Courier provides an API designed for developers to enhance user notification delivery by intelligently routing messages across various existing channels, such as email and messaging platforms. The API takes into account factors like user online status and previous engagement levels to determine the most effective communication method. Over the years, Courier has evolved significantly, continuously adapting to technological advancements to better serve its customers while maintaining stability in its management and operational approach. The company emphasizes the importance of customer success, fostering long-term relationships with its largest clients and collaborating closely to prepare for future developments in the industry.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
Celsius Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on the development and research of innovative drugs. Established in 2017, the company utilizes single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. This approach allows Celsius Therapeutics to identify critical biomarkers that can enhance patient care and contribute to the creation of transformative medicines. The company's commitment to advancing the understanding of complex diseases positions it as a key player in the biotechnology sector.
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.
Seismic Therapeutic is a biotechnology company focused on accelerating immunology drug development through the integration of machine learning in the biologics discovery process. Utilizing its IMPACT™ platform, Seismic Therapeutic aims to tackle key challenges in biologics discovery by combining structural biology, protein engineering, and translational immunology. This comprehensive approach facilitates the creation of optimized therapies that can reach patients more quickly. The company is developing a pipeline of innovative biologics targeting adaptive immune system dysregulation, with the goal of treating autoimmune diseases.
Mabl Inc. offers an automated testing service that leverages machine learning to identify regressions and automatically fix broken tests. Founded in 2016 and based in Boston, Massachusetts, the company provides a scriptless testing solution as part of its software-as-a-service (SaaS) offerings. Mabl facilitates machine-driven regression testing and integrates seamlessly into the continuous integration and continuous delivery (CI/CD) development lifecycle. Its platform allows software development teams to create, execute, and maintain auto-healing tests efficiently, ensuring the rapid delivery of high-quality applications. Mabl serves a range of enterprise clients, including Johnson Controls, Liberty Mutual, Molina Healthcare, JetBlue, Dollar Shave Club, and Charles Schwab, who rely on its services for testing their critical applications.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.
Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.
Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.
Lightmatter, Inc. is an artificial intelligence (AI) hardware company based in Boston, Massachusetts, that specializes in integrated optical technology to develop advanced computing processors. Founded in 2017, the company has created a silicon chip that utilizes light signals for processing, offering a new approach to AI computation. This technology accelerates critical operations in deep neural networks by employing programmable photonic elements alongside traditional transistors, enhancing the speed and efficiency of data processing while minimizing power consumption. Lightmatter's innovations aim to improve various AI applications, including image recognition and natural language processing, contributing to the advancement of next-generation AI-powered computing solutions.
Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.
Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
Superplastic, Inc. is a character-based product and entertainment company founded in 2017 and based in Burlington, Vermont. The company specializes in manufacturing and marketing limited edition art toys, apparel, games, and animation, featuring unique characters created in collaboration with renowned artists. Superplastic leverages the principles of effort and scarcity to enhance the value of its offerings, creating exclusive works of art for a select audience. The company also operates a platform that engages customers through various media, including animated videos and music, enabling interactions with its synthetic superstars in innovative ways. Products are primarily sold online, reflecting a modern approach to retail and entertainment.
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.
Invivyd is a biotechnology company focused on developing advanced antibodies to neutralize SARS-CoV-2, SARS-CoV-1, and other potentially emerging coronaviruses. Founded in 2020 and headquartered in Waltham, Massachusetts, the company aims to create best-in-class therapeutic and prophylactic treatments that surpass the efficacy of existing antibody programs. Its innovative portfolio features multiple non-competing antibodies, each targeting distinct viral epitopes, which is designed to minimize the risk of viral escape. By leveraging cutting-edge antibody discovery technologies, Invivyd seeks to enhance the potency and durability of its antibody candidates, addressing a critical need in the ongoing fight against coronaviruses.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle the early onset of various neurological diseases.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Merlin Labs is building an autonomous infrastructure for the sky above us, enabling goods, and eventually people, to fly without pilots.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
TScan Therapeutics is a biopharmaceutical company dedicated to developing innovative T cell therapies to treat various cancers, including liquid tumors and solid tumors. The company focuses on engineering T cell receptor (TCR) therapies, with specific candidates aimed at addressing hematologic malignancies and preventing relapse after hematopoietic stem cell transplantation. TScan utilizes a specialized platform that identifies shared T cell antigens and minimizes off-target effects, enhancing the safety and effectiveness of its treatments. The company’s pipeline includes both liquid tumor therapies and multiplexed TCR-T candidates for solid tumors. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and comprises a team of experts committed to expanding treatment options for patients with limited therapeutic alternatives.
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
Lola Travel Company, Inc. specializes in corporate travel management through its AI-driven platform, Lola.com. Established in 2015 and based in Boston, Massachusetts, the company provides a user-friendly tool for booking flights and hotels, managing itineraries, and tracking travel expenses. Its services include individual travel profiles, digital travel receipts, and budget management features, catering to the needs of businesses and their employees. Lola.com offers a range of functionalities designed to simplify business travel, such as transparent spending reports, team destination sharing, and 24/7 agent support. The platform also includes a "book on behalf" feature, allowing executive assistants to manage travel arrangements efficiently.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.
Lightmatter, Inc. is an artificial intelligence (AI) hardware company based in Boston, Massachusetts, that specializes in integrated optical technology to develop advanced computing processors. Founded in 2017, the company has created a silicon chip that utilizes light signals for processing, offering a new approach to AI computation. This technology accelerates critical operations in deep neural networks by employing programmable photonic elements alongside traditional transistors, enhancing the speed and efficiency of data processing while minimizing power consumption. Lightmatter's innovations aim to improve various AI applications, including image recognition and natural language processing, contributing to the advancement of next-generation AI-powered computing solutions.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Mabl Inc. offers an automated testing service that leverages machine learning to identify regressions and automatically fix broken tests. Founded in 2016 and based in Boston, Massachusetts, the company provides a scriptless testing solution as part of its software-as-a-service (SaaS) offerings. Mabl facilitates machine-driven regression testing and integrates seamlessly into the continuous integration and continuous delivery (CI/CD) development lifecycle. Its platform allows software development teams to create, execute, and maintain auto-healing tests efficiently, ensuring the rapid delivery of high-quality applications. Mabl serves a range of enterprise clients, including Johnson Controls, Liberty Mutual, Molina Healthcare, JetBlue, Dollar Shave Club, and Charles Schwab, who rely on its services for testing their critical applications.
Yesware, Inc. is a sales acceleration platform designed to assist sales professionals in enhancing their productivity and effectiveness. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware provides a suite of tools that includes email tracking, scheduling, reminders, call placements, and performance monitoring. The platform allows users to see when prospects open emails and click on links, facilitating timely follow-ups. Its features also include customizable email templates and integration with various Customer Relationship Management (CRM) systems like Salesforce and Microsoft Dynamics, streamlining workflows and improving data quality. Yesware offers different pricing plans, including a free tier that allows users to track a limited number of emails monthly, as well as options for teams and enterprises. The company's focus is primarily on B2B sales professionals, providing them with insights and tools to help achieve their sales objectives.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
Openbay, Inc. designs and develops SaaS based software for the automotive care industry. The company provides vehicle owners an online source for vehicle repair and maintenance needs. It connects customers with auto repair professionals that provide services, such as air conditioning services, battery replacements, belt replacements, brake pad and rotor replacements, exhaust system replacements, oil changes, radiator hose replacements, shock and strut replacements, spark plug replacements, steering component replacements, suspension component replacements, and tire replacements. The company was founded in 2011 and is based in Cambridge. Massachusetts.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Celsius Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on the development and research of innovative drugs. Established in 2017, the company utilizes single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. This approach allows Celsius Therapeutics to identify critical biomarkers that can enhance patient care and contribute to the creation of transformative medicines. The company's commitment to advancing the understanding of complex diseases positions it as a key player in the biotechnology sector.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.
Fractyl Health Inc. is a medical device company specializing in innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company's flagship product, Revita DMR, is a minimally invasive procedure that utilizes hydrothermal ablation to rejuvenate the lining of the duodenum, effectively addressing the underlying causes of these conditions. By focusing on transforming the treatment of metabolic diseases from merely managing symptoms to providing durable, disease-modifying solutions, Fractyl Health aims to significantly improve patient health outcomes. Founded in 2010 and based in Lexington, Massachusetts, the company is committed to developing curative therapies that lessen the burden on patients, healthcare providers, and payers.
Veo Robotics is transforming manufacturing with products that incorporate advanced computer vision, 3D sensing, and AI. Their first product lets high-performance industrial robots work collaboratively with people to enable much more flexible, productive, and efficient manufacturing workcells.
Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biology capabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC).
Toast, Inc. is a Boston-based technology company that specializes in developing an all-in-one point-of-sale and restaurant management software tailored for the foodservice and hospitality industries. Founded in 2011, Toast's cloud-based platform provides a comprehensive suite of features, including tableside ordering, online ordering, labor management, and real-time reporting, designed to enhance operational efficiency for restaurants, cafes, bars, and other food establishments. The software facilitates quick menu updates and integrates front-of-house and back-of-house operations, enabling restaurants to streamline their processes and improve guest experiences. With additional offices in Portland, Omaha, and Dublin, Toast aims to support restaurateurs in delivering exceptional service and achieving business success.
Toast, Inc. is a Boston-based technology company that specializes in developing an all-in-one point-of-sale and restaurant management software tailored for the foodservice and hospitality industries. Founded in 2011, Toast's cloud-based platform provides a comprehensive suite of features, including tableside ordering, online ordering, labor management, and real-time reporting, designed to enhance operational efficiency for restaurants, cafes, bars, and other food establishments. The software facilitates quick menu updates and integrates front-of-house and back-of-house operations, enabling restaurants to streamline their processes and improve guest experiences. With additional offices in Portland, Omaha, and Dublin, Toast aims to support restaurateurs in delivering exceptional service and achieving business success.
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.
Evelo Biosciences is a biotechnology company focused on developing oral biologics, specifically monoclonal microbials, for treating a range of inflammatory diseases and cancers. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company is advancing several candidates through various stages of clinical development. EDP1815, currently in a Phase 1b clinical study, aims to treat psoriasis and atopic dermatitis, while other candidates in pre-clinical stages target conditions such as psoriatic arthritis, asthma, and neuro-inflammatory diseases. Additionally, EDP1503 is undergoing Phase 1/2 trials for colorectal cancer and other malignancies. By utilizing naturally occurring monoclonal microbials, Evelo seeks to revolutionize drug discovery and development, offering a new approach to modulating systemic immunology and biology through oral delivery. This innovative platform has the potential to enhance the efficiency and effectiveness of treatments across various health conditions.
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing therapies aimed at protecting, repairing, and restoring hearing. The company focuses on a range of hearing disorders, including those related to cancer treatments, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as tinnitus. It utilizes advanced techniques such as single-cell genomics, bioinformatics, and precision gene therapy technologies to enhance its understanding of inner ear pathology and to develop effective treatments. Decibel Therapeutics also offers expertise in drug delivery to the inner ear, imaging, and pharmacokinetic modeling, contributing to innovative therapeutic approaches for patients experiencing various forms of hearing loss. Founded in 2013 and based in Boston, Massachusetts, Decibel Therapeutics was previously known as Hearing, Inc. before rebranding in 2014.
LevelUp is focused on creating advanced mobile experiences for over 200 brands across the United States, facilitating customer engagement and sales growth through a comprehensive platform. This platform includes a variety of features such as mobile rewards, payments, online ordering, customer relationship management, and loyalty programs. By consolidating data from in-store and online transactions, LevelUp enables merchants to design and execute targeted marketing campaigns that aim to boost customer spending and frequency. The company has established strategic partnerships with major organizations, providing restaurants access to a broader customer base beyond their own applications. LevelUp distinguishes itself by developing a mobile payment network that positions businesses to adapt to future changes in the mobile landscape.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing treatments for patients with genetically defined diseases, particularly in areas of high unmet medical need. Headquartered in Cambridge, Massachusetts, the company is advancing its lead product candidate, losmapimod, which is currently in a Phase 2b clinical trial for facioscapulohumeral muscular dystrophy, a rare and progressive muscle-wasting disorder. Additionally, Fulcrum is developing FTX-6058, a small molecule aimed at increasing fetal hemoglobin levels in patients with sickle cell disease and β-thalassemia. The company is also engaged in drug discovery efforts targeting conditions such as Duchenne muscular dystrophy, Friedreich ataxia, and α-synucleinopathies, as well as other neurological and pulmonary diseases. Fulcrum has established collaborations with Acceleron Pharma to explore biological targets in pulmonary diseases and with MyoKardia for the development of therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics is committed to delivering innovative solutions for patients facing significant health challenges.
Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.
ZappRx, Inc. is a digital health company based in Boston, Massachusetts, focused on modernizing the management of specialty medications. Its cloud-based prescription and prior authorization platform enhances efficiency for healthcare providers, specialty pharmacies, and biopharma companies by streamlining the ordering process for specialty drugs. The platform facilitates secure, collaborative interactions among providers, pharmacists, and payers, significantly reducing reliance on traditional communication methods like faxes and phone calls. ZappRx's services are particularly utilized in pulmonary, cardiology, and gastroenterology fields. The company was incorporated in 2012 and, as of June 2019, operates as a subsidiary of Allscripts Healthcare Solutions, Inc.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company's key product candidates include tebipenem pivoxil hydrobromide, an oral antibiotic aimed at treating MDR gram-negative infections in adults; SPR206, an intravenous agent targeting MDR gram-negative infections in hospital settings; and SPR720, an oral antibiotic for pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has entered various agreements, including a licensing partnership with Meiji Seika Pharma to develop tebipenem HBr and collaborations with Everest Medicines and the Bill & Melinda Gates Medical Research Institute for the development and commercialization of SPR206 and SPR720, respectively. Founded in 2013, Spero Therapeutics aims to address urgent medical needs through innovative therapeutic solutions for serious bacterial infections.
Lola Travel Company, Inc. specializes in corporate travel management through its AI-driven platform, Lola.com. Established in 2015 and based in Boston, Massachusetts, the company provides a user-friendly tool for booking flights and hotels, managing itineraries, and tracking travel expenses. Its services include individual travel profiles, digital travel receipts, and budget management features, catering to the needs of businesses and their employees. Lola.com offers a range of functionalities designed to simplify business travel, such as transparent spending reports, team destination sharing, and 24/7 agent support. The platform also includes a "book on behalf" feature, allowing executive assistants to manage travel arrangements efficiently.
Desktop Metal, Inc. specializes in additive manufacturing solutions tailored for engineers, designers, and manufacturers across various industries, including automotive, aerospace, healthcare, and consumer products. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers several products, such as the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System for office environments, and Fiber, a desktop 3D printer. By focusing on the entire production process from prototyping to mass production, Desktop Metal aims to transform how metal parts are designed and manufactured. The company has secured significant equity funding from notable investors, which has helped build a team of experts in materials science, hardware and software engineering, and design.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Plexxi, an affinity-driven networking solutions provider, develops an optimized network that improves the performance of applications. The company offers networking solutions for data center computing needs. It delivers converged, application-defined network infrastructure building blocks and systems for building software-defined data centers and public/private clouds. The solutions enable Cloud Builders to harness the power of a single, simple platform to create private/public/hybrid cloud and data center networks.
Toast, Inc. is a Boston-based technology company that specializes in developing an all-in-one point-of-sale and restaurant management software tailored for the foodservice and hospitality industries. Founded in 2011, Toast's cloud-based platform provides a comprehensive suite of features, including tableside ordering, online ordering, labor management, and real-time reporting, designed to enhance operational efficiency for restaurants, cafes, bars, and other food establishments. The software facilitates quick menu updates and integrates front-of-house and back-of-house operations, enabling restaurants to streamline their processes and improve guest experiences. With additional offices in Portland, Omaha, and Dublin, Toast aims to support restaurateurs in delivering exceptional service and achieving business success.
PatientPing, Inc. operates a national care coordination network designed to connect healthcare providers through real-time notifications when patients receive care. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers technology solutions for various healthcare stakeholders, including Accountable Care Organizations, hospitals, payers, and post-acute care facilities. Its network comprises a range of healthcare professionals, such as emergency case managers, primary care physicians, and care coordinators, facilitating improved collaboration and information sharing. PatientPing also features a tool called Spotlights, which analyzes real-time data to identify trends in healthcare utilization and performance. The company has formed a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC, focusing on enhancing patient outcomes and experiences through coordinated care.
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.
Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.
Panorama Education, based in Boston, Massachusetts, is a data analytics company focused on K-12 education. Founded in 2012, it offers a software-as-a-service platform that enables school districts, charter networks, and state governments to conduct comprehensive surveys of students, parents, teachers, and staff. The platform provides research-based surveys and delivers feedback data, allowing educators and administrators to analyze results across various demographics and school environments. By collecting feedback on individual teachers and overall school conditions, Panorama Education aims to enhance professional development and improve educator evaluation systems. The company also offers implementation consultation, technical assistance, and training to support its clients in effectively utilizing their data.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
Yesware, Inc. is a sales acceleration platform designed to assist sales professionals in enhancing their productivity and effectiveness. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware provides a suite of tools that includes email tracking, scheduling, reminders, call placements, and performance monitoring. The platform allows users to see when prospects open emails and click on links, facilitating timely follow-ups. Its features also include customizable email templates and integration with various Customer Relationship Management (CRM) systems like Salesforce and Microsoft Dynamics, streamlining workflows and improving data quality. Yesware offers different pricing plans, including a free tier that allows users to track a limited number of emails monthly, as well as options for teams and enterprises. The company's focus is primarily on B2B sales professionals, providing them with insights and tools to help achieve their sales objectives.
Bloom
Initial Coin Offering in 2015
Bloom is unveiling its first generation of products aimed to combat dementia, and (perhaps equally as important) the disintegration of communication among families. The Company provides a smart device that enable family members to connect and ensure each other's well-being.
Adelphic, Inc. develops a mobile and cross-channel programmatic advertising platform that connects brands with audiences. The company offers a campaign management portal that allows non-technical users to plan, create, launch, and optimize campaigns; Audience Cube, a tool that captures terabytes of data to develop custom segments and powerful insights and assign them to individual data records; and predictive performance engine solutions. It serves agencies, brands, and other large media buyers. Adelphic, Inc. was incorporated in 2011 and is based in Waltham, Massachusetts. As of February 27, 2017, Adelphic, Inc. operates as a subsidiary of Viant Technology Inc.
Tamr is an enterprise data unification company that is cost-effective, scalable, and accessible to any enterprise.
Following the success of initial research at MIT CSAIL, the Tamr team began building a commercial-grade solution designed to tackle the challenge of connecting and enriching diverse data at scale, quickly and cost effectively.
Launched in the spring of 2014 and backed by a series of investors, such as Google Ventures and New Enterprise Associates, Tamr is deployed in production at a variety organizations, including information services providers, pharmaceutical firms and retailers. Tamr, based in Cambridge, Massachusetts, was founded in 2013 by database industry veterans Andy Palmer, Mike Stonebraker and Ihab Ilyas with George Beskales, Daniel Bruckner and Alex Pagan.
Kensho Technologies, Inc. provides analytics, artificial intelligence, machine learning, and data visualization systems to global banks and investment institutions. It develops Kensho Financial Analytics Software that deploys scalable analytics systems across the commercial institutions. It also offers artificial intelligence (AI) software called Kensho Applied Mind. The company also operates a national security division called Koto. The company was incorporated in 2012 and is based in Cambridge, Massachusetts. It has additional offices in New York, New York; McLean, Virginia; and Pacific Palisades, California. As of April 8, 2018, Kensho Technologies, Inc. operates as a subsidiary of S&P Global Inc.
Yesware, Inc. is a sales acceleration platform designed to assist sales professionals in enhancing their productivity and effectiveness. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware provides a suite of tools that includes email tracking, scheduling, reminders, call placements, and performance monitoring. The platform allows users to see when prospects open emails and click on links, facilitating timely follow-ups. Its features also include customizable email templates and integration with various Customer Relationship Management (CRM) systems like Salesforce and Microsoft Dynamics, streamlining workflows and improving data quality. Yesware offers different pricing plans, including a free tier that allows users to track a limited number of emails monthly, as well as options for teams and enterprises. The company's focus is primarily on B2B sales professionals, providing them with insights and tools to help achieve their sales objectives.
Openbay, Inc. designs and develops SaaS based software for the automotive care industry. The company provides vehicle owners an online source for vehicle repair and maintenance needs. It connects customers with auto repair professionals that provide services, such as air conditioning services, battery replacements, belt replacements, brake pad and rotor replacements, exhaust system replacements, oil changes, radiator hose replacements, shock and strut replacements, spark plug replacements, steering component replacements, suspension component replacements, and tire replacements. The company was founded in 2011 and is based in Cambridge. Massachusetts.
Yesware, Inc. is a sales acceleration platform designed to assist sales professionals in enhancing their productivity and effectiveness. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware provides a suite of tools that includes email tracking, scheduling, reminders, call placements, and performance monitoring. The platform allows users to see when prospects open emails and click on links, facilitating timely follow-ups. Its features also include customizable email templates and integration with various Customer Relationship Management (CRM) systems like Salesforce and Microsoft Dynamics, streamlining workflows and improving data quality. Yesware offers different pricing plans, including a free tier that allows users to track a limited number of emails monthly, as well as options for teams and enterprises. The company's focus is primarily on B2B sales professionals, providing them with insights and tools to help achieve their sales objectives.
SynapDx is a laboratory services company focused on developing blood tests aimed at the early identification of children at risk for autism spectrum disorders (ASDs). Founded by Stanley Lapidus and headquartered in Lexington, Massachusetts, the company collaborates with experts in ASD and gene expression from leading institutions to enhance the effectiveness of its diagnostic tests. With the aim of enabling earlier detection, SynapDx serves physicians evaluating children for developmental disorders, addressing a critical need as autism is estimated to affect 1 in 110 children in the United States. The company secured initial venture funding in 2010, which has supported its mission to improve diagnostic capabilities for ASDs.
Objective Logistics is a Google and Atlas Venture-funded company that helps lift sales and improve the guest experience in restaurants, retail stores, and other industries nation-wide.
MUSE, a web-based software platform, motivates, measures, and mentors staff, giving them real-time rewards and active, up-to-the-minute data on their performance. Its ranking platform is combined with an automated service that rewards top performers with their preferred shifts and other non-monetary compensation.
MUSE, a Moneyball-Esque Performance Management tool is now commercially available for the restaurant industry and is in development for leading enterprises in a variety of new markets.
Nifti enables users to store and track products and their prices from their favorite websites.
Disruptor Beam brings together worldwide fan communities with games created surrounding iconic properties. It creates highly authentic, socially-driven games based around worlds that have spawned communities of millions of passionate, dedicated fans. The company was founded in 2010 and headquartered in Framingham, Massachusetts.
CustomMade Ventures Corp. is an online marketplace that connects consumers seeking unique, customized home furnishings and other personalized items with professional makers. Founded in 1996 and based in Cambridge, Massachusetts, the platform features a diverse range of products, including furniture, jewelry, home décor, and outdoor furnishings. Over the years, CustomMade has expanded its network from a small community of carpenters to over 12,000 skilled makers across various trades. The company aims to provide a seamless experience for buyers by combining personalized customer service with the expertise of its makers, making custom goods accessible and efficient to procure.
Adelphic, Inc. develops a mobile and cross-channel programmatic advertising platform that connects brands with audiences. The company offers a campaign management portal that allows non-technical users to plan, create, launch, and optimize campaigns; Audience Cube, a tool that captures terabytes of data to develop custom segments and powerful insights and assign them to individual data records; and predictive performance engine solutions. It serves agencies, brands, and other large media buyers. Adelphic, Inc. was incorporated in 2011 and is based in Waltham, Massachusetts. As of February 27, 2017, Adelphic, Inc. operates as a subsidiary of Viant Technology Inc.
TrueLens specializes in analyzing Socialgraphic data to enhance marketing strategies for prominent brands, including Adidas and Neiman Marcus. By leveraging insights from customer interactions and behaviors, TrueLens aims to help businesses better understand their target audiences and improve engagement. The company focuses on influencer marketing and content promotion, providing tools that enable brands to drive more effective results in their marketing efforts. Through comprehensive data analysis, TrueLens assists clients in optimizing their marketing initiatives to connect more effectively with customers and prospects.
HubSpot, Inc. is a provider of a cloud-based software platform designed for marketing, sales, and customer service, catering primarily to mid-market business-to-business companies. The platform encompasses a suite of integrated applications, including customer relationship management, search engine optimization, content management, email marketing, marketing automation, and analytics. With these tools, businesses can enhance their online marketing strategies, effectively engage with leads, and streamline customer interactions. Founded in 2005 and headquartered in Cambridge, Massachusetts, HubSpot has evolved from its initial focus on inbound marketing to a broader suite of services that support business growth. The company also offers professional support services via phone, email, and chat, ensuring comprehensive assistance for its users.
Foundation Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in molecular information products that analyze cancer specimens to provide genomic insights for personalized treatment. The company's platform employs proprietary methods to assist physicians in optimizing cancer therapies and supports biopharmaceutical companies in developing targeted treatments and immunotherapies. Its clinical products include FoundationOne for solid tumors, FoundationOne Heme for blood cancers, and several diagnostic assays aimed at specific cancer types, such as Foundation Assay for Circulating Tumor and FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine offers FoundationCORE, a knowledgebase that promotes advancements in oncology. The company engages in strategic collaborations with notable organizations, including F. Hoffmann-La Roche Ltd. and Genentech, to enhance precision medicine and develop companion diagnostics. Founded in 2009, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc.
Founded in 2011 by avid golfer Krishna Ramchandran, Ubersense produces mobile video analysis applications that enhance athletic performance across 20 different sports. Available free-of-charge through the Apple App Store, Ubersense apps are compatible over the iPhone, iPad and iTouch. Ubersense’s video coaching mobile applications have been adopted by more than one million amateur and professional athletes and coaches worldwide as a vital instruction tool. Additionally, Ubersense apps are utilized by eight U.S. Olympic teams and more than 100 U.S. university sports teams.